Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

AddSecure CEO named IoT Executive of the Year at 2024 IoT Global Awards

AddSecure's CEO, Stefan Albertsson, has been awarded the esteemed title of IoT Executive of the Year at the latest IoT Global Awards, a renowned program recognizing innovation and talent in the IoT industry.AddSecure , a leading provider of secure IoT connectivity and end-to-end solutions, is proud to announce that its CEO, Stefan Albertsson, has been honored with the prestigious title of IoT Executive of the Year at the latest edition of the IoT Global Awards. The IoT Global Awards is a renowned awards program that recognizes the most innovative

Read original

Inside information: Thomas Hinnerskov appointed President and CEO of Valmet

Inside information: Thomas Hinnerskov appointed President and CEO of Valmet   Valmet Oyj’s stock exchange release (inside information) on February 19, 2024 at 10:30 a.m. EET   Valmet’s Board of Directors has appointed Thomas Hinnerskov President and CEO of Valmet and he will start in the position during the second half of the year and at the end of September 2024 at the latest. Thomas Hinnerskov succeeds Pasi Laine, who will continue as the President and CEO of Valmet until his successor starts.   Thomas Hinnerskov is a Danish citizen and was born in 1971. He joins Valmet

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results

Oslo, Norway, 19 February 2024: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2023 financial results on Wednesday 21 February 2024 at 08:00 CET and will present a live webcast at 14:00 CET the same day.The quarterly report and presentation will be published at 08:00 CET and will be publicly available at www.photocure.com. The investor presentation will be streamed live and be hosted by Dan Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is

Stena Line’s CEO Niclas Mårtensson appointed to lead the Supply Chain & Transport Industry Community at the World Economic Forum

Niclas Mårtensson, CEO at Stena Line, is the new Governor Chair of the Supply Chain & Transport Industry Community at the World Economic Forum. Niclas Mårtensson will represent Stena AB, playing a critical role in accelerating the transformation of the industry over the next two years.The World Economic Forum (WEF) is an international organisation that brings together leaders from business, government, civil society, and academia to shape global, regional and industry agendas. At this year’s annual meeting in Davos, it was announced that Niclas Mårtensson will take on the role of Governor

Compliance with Market Abuse Regulations

19 February 2024   Fidelity Japan Trust PLC (the “Company”)   LEI: 549300ND695NEJ5GP172   Compliance with Market Abuse Regulations   The Company wishes to notify the market that the closed period of the Company in relation to its annual results for the period ended 31 December 2023 will commence on 19 February 2024 (today) and is anticipated to end no sooner than 19 March 2024.   The Company confirms that all inside information (as defined in the EU Market Abuse Regulation) which the Directors and the Company may have held has been notified to a regulatory

Four restaurants and two bars – Viking Cinderella offers foodies many new taste experiences

In early March, Viking Cinderella's passengers will have four new restaurants and two new bars to choose from when the vessel is placed in service on the Helsinki–Stockholm route, working in tandem with Viking Gabriella. Along with good food, there is also the promise of first-class service since many people were keen to work on board the vessel, which has now been reflagged under a Finnish flag.For Finnish passengers, good food is by far the most important ingredient for a successful cruise experience. That was a finding in a market survey* just carried out on Viking Line's behalf. Of the

Stena Line’s CEO Niclas Mårtensson appointed to lead the Supply Chain & Transport Industry Community at the World Economic Forum

Niclas Mårtensson, CEO at Stena Line, is the new Governor Chair of the Supply Chain & Transport Industry Community at the World Economic Forum. Niclas Mårtensson will represent Stena AB, playing a critical role in accelerating the transformation of the industry over the next two years.The World Economic Forum (WEF) is an international organisation that brings together leaders from business, government, civil society, and academia to shape global, regional and industry agendas. At this year’s annual meeting in Davos, it was announced that Niclas Mårtensson will take on the role of Governor

Prostatype Genomics’ long-term study with Uppsala University Hospital will be presented at the AUA conference in the US in May 2024

Prostatype Genomics announces that the interim results from the long-term follow-up study with the genetic test Prostatype®, which is conducted by and in collaboration with Uppsala University Hospital, has been accepted for presentation at the annual AUA (American Urological Association) conference in the United States in May 2024. To be accepted for presentation at this leading urology conference in the world’s largest market for prostate cancer diagnostics and prediction shows that there is a substantial interest for the study and the clinical potential of Prostatype® among American

BioStock: Medivir's CEO comments on the latest developments

As Medivir reports its fourth quarter, the company’s focus is on the further improved clinical efficacy of fostrox in combination with Lenvima in liver cancer. After recently having strengthened the cash position by more than 140 million SEK, now the aim is to accelerate the initiation of a pivotal phase IIb study and apply for accelerated approval from the FDA. BioStock reached out to CEO Jens Lindberg for a comment.Read the full interview with Jens Lindberg at biostock.se: https://www.biostock.se/en/2024/02/medivirs-ceo-comments-on-the-latest-developments/ This is a press release

Bio-Works publishes year end report for January-December 2023

A challenging year for biotech and for Bio-Works July – December 2023 · Net sales decreased by 6% to 21.8 (23.2) MSEK. Sales in Europe continued to be strong in the second half as a result of orders made prior to the period. The economic slow-down in North America had a negative impact on sales in the period. · Order intake* decreased by 70% to 10.2 (34.3) MSEK. The economic slow-down in our main markets has made some of our customers delay production and investments in new projects. The distribution of orders over Q3 and Q4 was 2.8 MSEK and 7.4 MSEK, respectively. · Profit in

BioStock: Full speed ahead for Elicera in 2024

Elicera Therapeutics has kicked off the year in boost mode. The Swedish cell and gene therapy company will get moving on the newly approved phase I/IIa study with lead CAR T candidate ELC-301, made possible by a major financing round coming later this month. Speaking to Elicera’s CEO Jamal El-Mosleh, it’s clear that the company is ready for a busy 2024, where now two pipeline candidates are in the clinic.Read the full interview with Jamal El-Mosleh at biostock.se: https://www.biostock.se/en/2024/02/full-speed-ahead-for-elicera-in-2024/ This is a press release from BioStock -

Buybacks of shares in ITAB during week 7 2024

During the period between 12 and 16 February 2024, ITAB Shop Concept AB (publ) (”ITAB”) (LEI-code: 2138001H6FCSZBP26351) has repurchased in total 273,763 own ordinary shares (ISIN: SE0015962097) as part of the share buyback program initiated by the Board of Directors in order to optimise the capital structure.The share buybacks form part of the share buyback program in a maximum amount of MSEK 50 that ITAB announced on 28 September 2023. The share buyback program, which runs from 29 September 2023 until 14 May 2024, is being carried out in accordance with the EU Market Abuse Regulation (“

COSEL launches enhanced reliability power supplies for industrial applications

•    Low component count for extended reliability•    For system’s upgrade - Form-Fit Function 100% compatible with the PBA series•    Safety approvals UL62368-1, c-UL (equivalent to CAN/CSA-22.2 No.62368-1), EN62368-1•    Wide operating temperature range -20 to +70 degrees C•    High reliability – 5-year warranty COSEL Co, Ltd (6905: Tokyo) has announced the launch of the PDA series  of AC/DC power supplies with further enhanced reliability for industrial applications. In order to offer the highest price/performance ratio while

University of Saarland chooses Sectra Education Portal to bridge the gap to clinical reality for radiographer students

Linköping, Sweden – February 19, 2024 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) will provide the University of Saarland with its platform for medical education—Sectra Education Portal. The platform provides real-life clinical cases, which will enhance the educational experiences for radiographer students, as well as elevate self-directed learning and remote studies. By adding Sectra’s solution for medical education to their existing Sectra enterprise imaging solution, they are bridging the gap between education and the clinical

Valmet’s share buy-back program for its share-based incentive plans has ended

Valmet’s share buy-back program for its share-based incentive plans has ended Valmet Oyj’s press release on February 19, 2024 at 9:30 a.m. EET   Valmet has now completed the share buy-back program for its share-based incentive plans. The acquisitions of the own shares began on February 12, 2024, and ended on February 16, 2024. During that period, Valmet acquired in aggregate 100,000 of its own shares for an average price per share of EUR 25.58. The total purchase price paid for the shares was EUR 2,557,818. The shares were acquired at market price in public trading on Nasdaq

Wulff Group Plc’s Financial Statements Release January 1 – December 31, 2023

FINANCIAL STATEMENTS RELEASE | FEBRUARY 19, 2024 AT 9.30 A.M. This is a summary of Wulff Group Plc’s Financial Statements Release January 1–December 31, 2023. The complete report is attached to this stock exchange release as a pdf-file. The report is also available at the website www.wulff.fi Positive profitability development in Q4, a proposal for a growing dividend 1.10.-31.12.2023 BRIEFLY · Net sales decreased by 17.1% and totalled EUR 22.9 million (27.7) · EBITDA was EUR 1.6 million (1.8), and comparable EBITDA was EUR 1.6 million (1.8) · Operating profit (EBIT) was

Continued demand for Quartzene[®] in cool roof paint – Svenska Aerogel receives 3 ton order

Svenska Aerogel receives a call-off order for 3 tons of Quartzene[®] from its French distributor Novcoat. The order thus represents a delivery contract between the two companies for 2024 and will be divided into four deliveries during the year. The material will be used by Novcoat’s customer in cool roof paint.When planning its deliveries for 2024, Novcoat’s customer ordered a total of 3 tons of Quartzene®. The value of the order is 96.8 KEUR.   Tor Einar Norbakk, CEO of Svenska Aerogel, comments: ”This order is a very positive sign for us, as it indicates continued strong growth for

BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise

Last year, a lot of focus for Curasight revolved around prostate cancer and the licensing deal with Curium. Now, the company has announced the next step for the theranostic approach and its wish to accelerate clinical development of both uTREAT and uTRACE in parallel. Curasight aims at starting a phase I/IIa basket trial in several indications and in order to finance this updated develoment strategy, the company aims at raising DKK 51.2 million in a rights issue. BioStock contacted CEO Ulrich Krasilnikoff to learn more.Read the full article at biostock.se: https://www.biostock.se/en/2024/

Tagrisso plus chemo approved in US for lung cancer

19 February 2024 Tagrisso with the addition of chemotherapy approved in the  US for patients with EGFR-mutated advanced lung cancer Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care AstraZeneca's Tagrisso (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval following a Priority

Notice convening YIT Corporation’s Annual General Meeting

YIT Corporation Stock Exchange Release 19 February 2024 at 09:10 a.m.Notice convening YIT Corporation’s Annual General Meeting The shareholders of YIT Corporation are invited to attend the Annual General Meeting to be held on Thursday,14 March 2024, starting at 11:00 a.m. Finnish time (GMT+2) in Messukeskus Siipi, located at the address Rautatieläisenkatu 3, 00520 Helsinki, Finland. Check-in for those who have registered for the meeting, the distribution of voting tickets and coffee service will start at the meeting venue at 10:00 a.m. Finnish time. Shareholders may also exercise

Invitation to Fourth Quarter 2023 Results

Oslo, 19 February 2024: BlueNord ASA ("BlueNord" or the "Company") will publish its financial results for the fourth quarter of 2023 on Tuesday 20 February 2024 at 07:00 (CET). A webcast presentation, followed by a Q&A session, will be hosted at 10:00 (CET). To join webcast: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20240220_4 *** Contact: Cathrine Torgersen, Chief Corporate Affairs OfficerEmail: cathrine.torgersen@bluenord.comPhone: +47 915 28 501

FDA accepts Dato-DXd BLA for nonsquamous NSCLC

19 February 2024 Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer Application based on results from the TROPION-Lung01 Phase III trial If approved, AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan may bethe first TROP2-directed antibody drug conjugate for patients with lung cancer AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally

There are no items matching the current filter
There are no more items matching the current filter
Back to top